Zacks Investment Research downgraded shares of TETRAPHASE PHAR (TTPH) from OUTPERFORM to NEUTRAL on January 02, 2015, with a target price of $43.80.
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on TETRAPHASE PHAR (TTPH),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment